AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis
doi 10.1136/annrheumdis-2018-eular.5146
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2018
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism